RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
NCT ID: NCT04139993
Last Updated: 2023-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
3 participants
INTERVENTIONAL
2020-08-31
2023-01-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
NCT04616183
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
NCT05502913
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
NCT02933944
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT04854434
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
NCT07321106
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine the safety and tolerability of microbiota-based formulation RBX7455 (RBX7455) given for at least 2 weeks and not more than 4 weeks prior to surgery.
II. To evaluate intratumoral immunomodulatory effects, including tumor infiltrating lymphocytes ( TILs), CD4, and CD8 T cells, in operable breast cancer patients.
SECONDARY OBJECTIVES:
I. To evaluate systemic immunomodulatory effects of RBX7455 by measuring circulating cytokines including IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8 (IL-8), IL-10, IL-12, IL-13, IL- 17A, IFN-gamma, TNF-alpha, CCL2 (MCP-1), CCL4 (MIP-1beta), granulocyte-colony stimulating factor (G-CSF), and granulocyte macrophage (GM)-CSF before and after treatment with RBX7455.
II. To assess stool microbiome α-diversity, bacterial abundance, and bacterial taxonomy before and after treatment with RBX7455.
III. To assess the durability of bacterial engraftment of RBX7455 in the stool at 8 weeks and 6 months.
OUTLINE:
Prior to standard of care surgery, patients receive RBX7455 orally (PO) 4 days a week for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of surgery, patients are followed up at 8 weeks and 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (RBX7455)
Prior to standard of care surgery, patients receive RBX7455 orally (PO) 4 days a week for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
Microbiota-based Formulation RBX7455
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microbiota-based Formulation RBX7455
Given PO
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed un-resected operable invasive adenocarcinoma of the breast \>= 0.5cm
* For cohort 1: Estrogen receptor (ER) and/or progesterone receptor (PR) positive \>= 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression
* For cohort 2: Human epidermal growth factor receptor 2 (HER2) amplification with fluorescence in situ hybridization (FISH) ratio \>= 2.0 or overexpression by immunohistochemistry 3+ with any ER and/or PR
* For cohort 3: Triple negative. Estrogen receptor (ER) and/or progesterone receptor (PR) negative \< 10%, and no human epidermal growth factor receptor 2 (HER2) amplification or overexpression
* Patients must not receive neoadjuvant chemotherapy prior to surgery
* Absolute neutrophil count (ANC) \>= 1000/mm\^3
* Platelet count \>= 75,000/mm\^3
* Hemoglobin \>= 9.0 g/dL
* Creatinine =\< 2 x upper limit of normal (ULN)
* Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< 2 x ULN
* Albumin \>= 3 g/dL
* Willing and able to swallow capsules
* Willing and able to complete the stool and serum testing required for the study
* Willing to provide blood samples for correlative research purposes
* Agrees not to take non-dietary probiotics through 8 weeks after receiving the course of study drug (including over-the counter \[OTC\] and prescription)
* Agrees not to take any oral vancomycin, metronidazole, fidaxomicin, rifaximin, nitazoxanide, bezlotoxumab and intravenous immunoglobulin therapy (IVIG) through the 8-week follow-up assessment unless newly prescribed by a treating investigator during the course of the study
* Willing to employ adequate contraception from the time of enrollment through 3 months after the final dose of RBX7455
* Note: Adequate contraception methods include birth control pills, barrier device, intrauterine device
* Capable of understanding the investigative nature, potential risks, and benefits of the study
* Capable of providing valid informed consent
* Willing to return to enrolling institution for all study visits (blood draws, etc)
* Willing and able to complete the required Patient Medication Diary
* Willing and able to meet all study requirements, including attending all assessment visits and telephone calls
* Women of child bearing potential must have negative pregnancy test within 7 days of enrollment
Exclusion Criteria
* Fecal microbiota transplant (FMT) within the past 6 months
* FMT with an associated serious adverse event related to the FMT product or procedure
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimen
* Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive or those on chronic steroids \> 20 mg prednisone a day or prednisone-equivalent
* Note: Must be off systemic steroids at least 90 days prior to enrollment. However, topical steroids, inhalants or steroid eye drops are permitted
* Receiving any other investigational agent
* History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis
* Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria
* History of chronic diarrhea
* History of celiac disease
* Currently has a colostomy
* Intraabdominal surgery related to gastrointestinal tract within the last 60 days
* Evidence of active, severe colitis
* History of short gut syndrome or motility disorders
* Requires the regular use of medications to manage bowel hypermotility
* Active autoimmune disease that has required systemic treatment in the =\< 30 days (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) prior to randomization. Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded
* Pregnancy
* Breast feeding
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria I Vazquez Roque
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Florida
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-02748
Identifier Type: REGISTRY
Identifier Source: secondary_id
19-004024
Identifier Type: OTHER
Identifier Source: secondary_id
19-004024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.